Secretomics uncovers blood-brain barrier mystery

Researchers identify novel gelatinase substrates involved in astroglial barrier function: In neuroinflammation, immune cells such as leukocytes cross the blood-brain barrier. One key to this is the gelatinases matrix metalloproteinase (MMP)-2 and -9. Until now, the substrates of these enzymes involved in the process were unknown.

Now, using a sensitive mass spectrometry-based secretome approach, researchers at the University of Münster and Bonn University Hospital (UKB) have succeeded in identifying hundreds of such molecules that are cleaved from the cell surface of astrocytes. In doing so, they have generated a unique database of MMP-2/-9 substrates specific to the formation and maintenance of the barrier as well as communication between astrocytes and neurons. The results have now been published in the journal Science Advances.

The endothelial cells on the inner wall of cerebral blood vessels form a protective barrier to the brain via tightly linked junctions. However, without the underlying astrocytes, a form of glial cells, a fully functional blood-brain barrier (BBB) cannot form. In neuroinflammation, the endothelial and astroglial layers are molecularly and functionally two distinct barriers to invading white blood cells, known as leukocytes. However, studies in multiple sclerosis (MS) show that disease symptoms do not develop until immune cells have also penetrated the astroglial layer. “This underscores their important contribution to the functional integrity of the BBB as well as their independence from the endothelial barrier,” says Prof. Lydia Sorokin, director of the Institute of Physiological Chemistry and Pathobiochemistry at the University of Münster. “But in contrast to leukocyte penetration of the endothelial barrier, there has been little knowledge of subsequent processes at the astroglial layer.”

Data on processes at the cell surface of astrocytes is thin

It is known that the gelatinases, matrix metalloproteinase (MMP)-2 and -9 regulate the invasion of leukocytes into the brain during neuroinflammation. Activity of these two protein-cleaving enzymes is thus an early marker of invasion of the brain parenchyma by these immune cells – to date, the only specific marker of ongoing neuroinflammation. “Evidence suggests that MMP-2 and MMP-9 have both positive and negative effects on the BBB. Therefore, deciphering their substrate specificity at the brain parenchymal boundary will contribute to the understanding of molecular processes essential for astroglial barrier function,” said Prof. Sorokin.

Sekretomic is the key to peptides from proteolytic cleavage

Identifying the enzyme cleavage sites is a challenge. The research team relies on recent advances in, among other things, mass spectrometry (MS) to analyze the secretome – a method that can comprehensively detect proteins secreted by cells. In this study, they further developed this method to identify proteolytic cleavages of cell membrane-associated proteins. “Our approach detects extracellularly released protein fragments independently of biochemical enrichments and is therefore particularly sensitive,” said Prof. Felix Meissner, director of the UKB’s Institute of Innate Immunity. Using a tailored secretome MS approach, the team identified two major classes of compounds released by MMP-2/MMP-9 from the astrocyte cell surface. Validation of these novel substrates of neuroinflammation was performed in the mouse model of multiple sclerosis and in human MS samples.

Overall, the combination of the secretome MS approach with knowledge of the astroglial barrier provides a unique database of previously unknown gelatinase substrates that likely contribute to the barrier function of the astroglial boundary. In addition, evidence suggests that MMP-2/MMP-9 activity may also influence communication between astrocytes and neurons. “Our approach to identify proteolytic processes that control astroglial barrier function works and provides opportunities for future research to understand the molecular nature of the astroglial barrier and its contribution to the BBB,” said Prof. Meissner.

Publication:
Miriam Burmeister et al; Secretomics Reveals Novel Gelatinase Substrates at the Blood-Brain Barrier that are Implicated in Astroglial Barrier Function; Science Advances; DOI: https://doi.org/10.1126/sciadv.adg0686

Press contact:
Dr. Inka Väth
Deputy Press Officer at the University Hospital Bonn (UKB)
Communications and Media Office at Bonn University Hospital
Phone: +49 228 287-10596
E-mail: inka.vaeth@ukbonn.de

About the University Hospital Bonn: The UKB cares for about 500,000 patients per year, employs 9,000 people and has a balance sheet total of 1.6 billion euros. In addition to the more than 3,300 medical and dental students, a further 585 people are trained each year in numerous healthcare professions. The UKB is ranked number one among university hospitals in NRW in the science ranking as well as in the Focus clinic list and has the third highest case mix index (case severity index) in Germany.

Wissenschaftliche Ansprechpartner:

Prof. Dr. Felix Meißner
Institute for Innate Immunity
Cluster of Excellence ImmunoSensation2
University Hospital Bonn/University of Bonn
Phone +49 228-28751210
E-mail: felix.meissner@uni-bonn.de

Originalpublikation:

Miriam Burmeister et al; Secretomics Reveals Novel Gelatinase Substrates at the Blood-Brain Barrier that are Implicated in Astroglial Barrier Function; Science Advances; DOI: https://doi.org/10.1126/sciadv.adg0686

Sekretomics deckt Rätsel um Blut-Hirn-Schranke auf